Grey Wolf Therapeutics Limited (United Kingdom)

Homepage: greywolftherapeutics.com

Alternate names: Grey Wolf Therapeutics Limited, Greywolf Therapeutics

ROR: 026dwz758

OpenAlex ID: I4405267319

EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance or MSS-CRC.

2026 · Fiona Thistlethwaite, Desamparados Roda, et al. · Journal of Clinical Oncology · 3

EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.

2024 · Thomas Lillie, Ganessan Kichenadasse, et al. · Journal of Clinical Oncology · 3

553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition

2021 · Peter Joyce, Martin Quibell, et al. · Journal for ImmunoTherapy of Cancer · 3

Abstract 4261: High-sensitivity HLA-I immunopeptidome profiling from limited clinical PBMC samples

2026 · Anamarija Pfeiffer, Lucy Yang, et al. · Cancer Research · 1

446 Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition

2020 · Peter Joyce, Lesley Young, et al. · Journal for ImmunoTherapy of Cancer · 1

Abstract 1768: High-sensitivity targeted mass spectrometry enables quantification of HLA-presented antigens for TCR-T therapeutic target discovery

2026 · Simonas Savickas, Anamarija Pfeiffer, et al. · Cancer Research

1561P EMITT-1: Final clinical, PK & PD data from dose escalation and selection of recommended dose for expansion cohorts in a phase I study of GRWD5769 (a first-in-class ERAP1i) in patients with solid malignancies

2025 · J.J. Liu, G. Kichenadasse, et al. · Annals of Oncology

Abstract 5838: Quantification of ERAP-1 inhibition-dependent HLA-I peptides using targeted mass spectrometry for TCR-based therapeutics target discovery

2025 · Anamarija Pfeiffer, Lucy Yang, et al. · Cancer Research

Abstract 5551: Potent oral ERAP1 inhibitors modify the immunopeptidome in vivo and are novel immunotherapy agents

2020 · Jamie Ware, Patrick McIntyre, et al. · Cancer Research

Works count: 9

Citation count: 42